{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:42:53Z","timestamp":1793162573718,"version":"4.5.0"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012331","name":"Flanders Innovation & Entrepreneurship","doi-asserted-by":"publisher","award":["HBC.2022.0149"],"award-info":[{"award-number":["HBC.2022.0149"]}],"id":[{"id":"10.13039\/100012331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejps.2025.107095","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:57:57Z","timestamp":1743901077000},"page":"107095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Small molecule drug absorption in inflammatory bowel disease and current implementation in physiologically- based pharmacokinetic models"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1910-8882","authenticated-orcid":false,"given":"Jonas","family":"Langeraert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Gasthuys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107095_bib0001","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2025.107095_bib0002","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0168-3659(93)90040-C","article-title":"Colonic transit of different sized tablets in healthy subjects","volume":"23","author":"Adkin","year":"1993","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejps.2025.107095_bib0003","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1016\/j.xphs.2022.07.012","article-title":"Quantitative assessment of the impact of Crohn's Disease on protein abundance of Human intestinal drug-metabolising enzymes and transporters","volume":"111","author":"Alrubia","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0004","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40262-022-01169-4","article-title":"Altered bioavailability and pharmacokinetics in Crohn's Disease: capturing systems parameters for PBPK to assist with predicting the fate of orally administered drugs","volume":"61","author":"Alrubia","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2025.107095_bib0005","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1208\/s12249-024-02803-z","article-title":"The effect of Inflammatory Bowel Disease and irritable Bowel Syndrome on Pravastatin oral Bioavailability: in vivo and in silico evaluation using bottom-up wbPBPK modeling","volume":"25","author":"Alsmadi","year":"2024","journal-title":"AAPS. PharmSciTech."},{"key":"10.1016\/j.ejps.2025.107095_bib0006","article-title":"Abu-Farsakh NA. Enhancing atorvastatin In vivo oral bioavailability in the presence of inflammatory bowel disease and irritable bowel syndrome using supercritical fluid technology guided by wbPBPK modeling in rat and Human","volume":"23","author":"Alsmadi","year":"2022","journal-title":"AAPS PharmSciTech [Internet]"},{"key":"10.1016\/j.ejps.2025.107095_bib0007","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1023\/A:1018903931777","article-title":"Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of Human intestinal epithelial cells and rat intestinal segments","volume":"10","author":"Artursson","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2025.107095_bib0008","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ejps.2013.08.027","article-title":"A review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption","volume":"57","author":"Augustijns","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0009","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1021\/mp060022d","article-title":"Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target","volume":"3","author":"Balakrishnan","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2025.107095_bib0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.gie.2008.01.033","article-title":"Intravenous application of fluorescein for confocal laser scanning microscopy: evaluation of contrast dynamics and image quality with increasing injection-to-imaging time","volume":"68","author":"Becker","year":"2008","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.ejps.2025.107095_bib0011","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ejps.2004.04.006","article-title":"Accuracy of calculated pH-dependent aqueous drug solubility","volume":"22","author":"Bergstr\u00f6m","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0012","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00000658-200001000-00006","article-title":"Risk factors for surgery and postoperative recurrence in Crohn's Disease","volume":"231","author":"Bernell","year":"2000","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ejps.2025.107095_bib0013","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ibd.20088","article-title":"Decreased P-glycoprotein (P-gp\/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels","volume":"13","author":"Blokzijl","year":"2007","journal-title":"Inflamm. Bowel. Dis."},{"key":"10.1016\/j.ejps.2025.107095_bib0014","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/gut.15.12.999","article-title":"Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device","volume":"15","author":"Bown","year":"1974","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2025.107095_bib0015","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.coph.2013.08.004","article-title":"Drug transport via the intestinal peptide transporter PepT1","volume":"13","author":"Brandsch","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107095_bib0016","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0005-2736(85)90189-0","article-title":"Regional differences in the lipid composition and fluidity of rat colonic brush-border membranes","volume":"819","author":"Brasitus","year":"1985","journal-title":"Biochim Biophys Acta BBA - Biomembr"},{"key":"10.1016\/j.ejps.2025.107095_bib0017","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/ibd\/izz021","article-title":"Confocal laser endomicroscopy in the evaluation of inflammatory bowel disease","volume":"25","author":"Buchner","year":"2019","journal-title":"Inflamm. Bowel. Dis."},{"key":"10.1016\/j.ejps.2025.107095_bib0018","first-page":"767","article-title":"Intestinal permeability to 99mTc-diethylenetriaminopentaacetic acid in inflammatory bowel disease","volume":"81","author":"Casellas","year":"1986","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejps.2025.107095_bib0019","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF01071972","article-title":"A study of intestinal function and morphology in nonspecific ulcerative colitis in acute phase and remission in India","volume":"18","author":"Chakravarti","year":"1973","journal-title":"Am. J. Dig. Dis."},{"key":"10.1016\/j.ejps.2025.107095_bib0020","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1053\/j.gastro.2017.05.056","article-title":"Impaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel disease and mucosal healing","volume":"153","author":"Chang","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2025.107095_bib0021","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ejps.2011.04.016","article-title":"Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids","volume":"43","author":"Clarysse","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0022","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1007\/s11095-009-9857-7","article-title":"Postprandial changes in solubilizing capacity of Human intestinal fluids for BCS class II drugs","volume":"26","author":"Clarysse","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2025.107095_bib0023","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1113\/jphysiol.1975.sp010891","article-title":"The interdigestive myo-electric complex of the stomach and small bowel of dogs","volume":"246","author":"Code","year":"1975","journal-title":"J. Physiol."},{"key":"10.1016\/j.ejps.2025.107095_bib0024","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1023\/A:1015849700421","article-title":"Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects","volume":"8","author":"Coupe","year":"1991","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2025.107095_bib0025","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ecco-jcc\/jjaa143","article-title":"Gut microbiota-driven drug metabolism in inflammatory bowel disease","volume":"15","author":"Crouwel","year":"2020","journal-title":"J. Crohns Colitis."},{"key":"10.1016\/j.ejps.2025.107095_bib0026","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3390\/pharmaceutics11080411","article-title":"Intestinal permeability and drug absorption: predictive experimental, computational and In vivo approaches","volume":"11","author":"Dahlgren","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejps.2025.107095_bib0027","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1021\/acs.molpharmaceut.6b00514","article-title":"Regional intestinal permeability of three model drugs in Human","volume":"13","author":"Dahlgren","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2025.107095_bib0028","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/jps.24258","article-title":"Direct In vivo Human intestinal permeability (Peff) determined with different clinical perfusion and intubation methods","volume":"104","author":"Dahlgren","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0029","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1136\/gut.27.8.886","article-title":"Transit of pharmaceutical dosage forms through the small intestine","volume":"27","author":"Davis","year":"1986","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2025.107095_bib0030","series-title":"Small Intestinal Transit. Drug Delivery Gastrointestinal Tract","first-page":"46","author":"Davis","year":"1989"},{"key":"10.1016\/j.ejps.2025.107095_bib0031","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1359-6446(04)03351-3","article-title":"Formulation strategies for absorption windows","volume":"10","author":"Davis","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2025.107095_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122282","article-title":"The impact of inflammation on the expression of drug transporters and metabolic enzymes in colonic tissue from ulcerative colitis patients","volume":"628","author":"de Waal","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2025.107095_bib0033","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrgastro.2012.57","article-title":"The migrating motor complex: control mechanisms and its role in health and disease","volume":"9","author":"Deloose","year":"2012","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejps.2025.107095_bib0034","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2010.11.034","article-title":"Gastrointestinal contents in fasted state and post-lipid ingestion: in vivo measurements and in vitro models for studying oral drug delivery","volume":"151","author":"Di Maio","year":"2011","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejps.2025.107095_bib0035","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s11095-009-9927-x","article-title":"Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults","volume":"26","author":"Diakidou","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2025.107095_bib0036","article-title":"Intestinal microbiology","author":"Drasar","year":"1985","journal-title":"Van Nostrand Reinhold"},{"key":"10.1016\/j.ejps.2025.107095_bib0037","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/cpt.967","article-title":"Protein abundance of clinically relevant drug-metabolizing enzymes in the Human liver and intestine: a comparative analysis in paired tissue specimens","volume":"104","author":"Drozdzik","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2025.107095_bib0038","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/cpt.1301","article-title":"Protein abundance of clinically relevant drug transporters in the Human liver and intestine: a comparative analysis in paired tissue specimens","volume":"105","author":"Drozdzik","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2025.107095_bib0039","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.3390\/molecules27092961","article-title":"Bile acids transporters of enterohepatic circulation for targeted drug delivery","volume":"27","author":"Durn\u00edk","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2025.107095_bib0040","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2036.2003.01426.x","article-title":"A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules","volume":"17","author":"Edsb\u00e4cker","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2025.107095_bib0041","article-title":"Gastrointestinal diseases and their impact on drug solubility: ulcerative Colitis","volume":"152","author":"Effinger","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0042","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jphp.12928","article-title":"Impact of gastrointestinal disease states on oral drug absorption \u2013 implications for formulation design \u2013 a PEARRL review","volume":"71","author":"Effinger","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107095_bib0043","article-title":"Gastrointestinal diseases and their impact on drug solubility: Crohn's disease","volume":"152","author":"Effinger","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0044","article-title":"Predicting budesonide performance in healthy subjects and patients with Crohn's disease using biorelevant in vitro dissolution testing and PBPK modeling","volume":"157","author":"Effinger","year":"2021","journal-title":"Eur. J. Pharm. Sci. [Internet]"},{"key":"10.1016\/j.ejps.2025.107095_bib0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0009-9236(99)70119-0","article-title":"Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease","volume":"65","author":"Egan","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2025.107095_bib0046","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ibd.20030","article-title":"Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and pgp (ABCB1)","volume":"13","author":"Englund","year":"2007","journal-title":"Inflamm. Bowel. Dis."},{"key":"10.1016\/j.ejps.2025.107095_bib0047","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1359-6446(96)10046-5","article-title":"Bile acids in drug discovery","volume":"3","author":"Enhsen","year":"1998","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2025.107095_bib0048","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gut.29.8.1035","article-title":"Measurement of gastrointestinal pH profiles in normal ambulant human subjects","volume":"29","author":"Evans","year":"1988","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2025.107095_bib0049","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1023\/A:1026664105112","article-title":"Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease","volume":"44","author":"Ewe","year":"1999","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0050","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11095-008-9749-2","article-title":"Meal-induced acceleration of tablet transit through the Human small intestine","volume":"26","author":"Fadda","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2025.107095_bib0051","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1211\/jpp.59.10.0002","article-title":"Prediction of human pharmacokinetics\u2014gut-wall metabolism","volume":"59","author":"Fagerholm","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107095_bib0052","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00054725-200608000-00011","article-title":"Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn\u02bcs disease","volume":"12","author":"Fakhoury","year":"2006","journal-title":"Inflamm. Bowel. Dis."},{"key":"10.1016\/j.ejps.2025.107095_bib0053","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2036.1989.tb00254.x","article-title":"pH-profile and regional transit times of the normal gut measured by a radiotelemetry device","volume":"3","author":"Fallingborg","year":"1989","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2025.107095_bib0054","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/BF01297074","article-title":"Very low intraluminal colonic pH in patients with active ulcerative colitis","volume":"38","author":"Fallingborg","year":"1993","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0055","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0016-5085(00)70210-1","article-title":"High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy","volume":"118","author":"Farrell","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2025.107095_bib0056","article-title":"Public workshop: evaluating inclusion and exclusion criteria in clinical","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.ejps.2025.107095_bib0057","unstructured":"FDA. Guidance for industry: enhancing the diversity of clinical trial populations \u2014 eligibility criteria, enrollment practices, and trial designs. 2020; Available from: https:\/\/www.fda.gov\/media\/127712\/download."},{"key":"10.1016\/j.ejps.2025.107095_bib0058","unstructured":"FDA. Pharmacokinetics in patients with impaired renal function \u2013 study design, data analysis, and impact on dosing guidance for industry. 2024; Available from: https:\/\/www.fda.gov\/media\/78573\/download."},{"key":"10.1016\/j.ejps.2025.107095_bib0059","series-title":"Hum Intest Microflora Health Dis [Internet]","first-page":"3","article-title":"CHAPTER 1 - normal indigenous intestinal flora","author":"Finegold","year":"1983"},{"key":"10.1016\/j.ejps.2025.107095_bib0060","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1208\/s12249-016-0521-3","article-title":"Assessment of small intestinal transit times in ulcerative colitis and Crohn's Disease patients with different disease activity using video capsule endoscopy","volume":"18","author":"Fischer","year":"2017","journal-title":"AAPS. PharmSciTech."},{"key":"10.1016\/j.ejps.2025.107095_bib0061","series-title":"Transport Processes in Pharmaceutical Systems","first-page":"38","article-title":"Biological transport phenomena in the gastrointestinal tract: cellular mechanisms","author":"Fleischer","year":"1999"},{"key":"10.1016\/j.ejps.2025.107095_bib0062","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3389\/fmicb.2016.01081","article-title":"The gut microbiota in immune-mediated inflammatory diseases","volume":"7","author":"Forbes","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejps.2025.107095_bib0063","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1111\/j.1572-0241.2005.00325.x","article-title":"Intestinal permeability and genetic determinants in patients, first-degree relatives, and controls in a high-incidence area of Crohn's Disease in Southern Italy","volume":"100","author":"Fries","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejps.2025.107095_bib0064","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12664-021-01211-6","article-title":"Small intestinal bacterial overgrowth in patients with inflammatory bowel disease: a case-control study","volume":"41","author":"Ghoshal","year":"2022","journal-title":"Indian J. Gastroenterol."},{"key":"10.1016\/j.ejps.2025.107095_bib0065","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3390\/microorganisms10071371","article-title":"Gut microbiome in inflammatory bowel disease: role in pathogenesis, dietary modulation, and colitis-associated colon cancer","volume":"10","author":"Gubatan","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.ejps.2025.107095_bib0066","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/nmo.12713","article-title":"Regional gastrointestinal transit times in severe ulcerative colitis","volume":"28","author":"Haase","year":"2016","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.ejps.2025.107095_bib0067","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3390\/pharmaceutics15092237","article-title":"Understanding discordance between In vitro dissolution, local gut and systemic bioequivalence of budesonide in healthy and Crohn's Disease patients through PBPK modeling","volume":"15","author":"Han","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2025.107095_bib0068","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.1039\/C9TB01081E","article-title":"Biomaterial\u2013tight junction interaction and potential impacts","volume":"7","author":"Han","year":"2019","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ejps.2025.107095_bib0069","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.1987.tb00620.x","article-title":"Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicylic acid tablet","volume":"1","author":"Hardy","year":"1987","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2025.107095_bib0070","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00018-008-7568-6","article-title":"Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics","volume":"65","author":"Hofmann","year":"2008","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0071","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000159379","article-title":"Diminished expression of apical sodium-dependent bile acid transporter in gallstone disease is independent of ileal inflammation","volume":"78","author":"Holzer","year":"2008","journal-title":"Digestion"},{"key":"10.1016\/j.ejps.2025.107095_bib0072","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s13346-022-01179-6","article-title":"Impact of gastric and bowel surgery on gastrointestinal drug delivery","volume":"13","author":"Hua","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejps.2025.107095_bib0073","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1007\/s11095-008-9580-9","article-title":"Interplay between intestinal pH, transit time and feed status on the In vivo performance of pH responsive ileo-colonic release systems","volume":"25","author":"Ibekwe","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2025.107095_bib0074","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/jps.20742","article-title":"An investigation into the in vivo performance variability of pH responsive polymers for ileo-colonic drug delivery using gamma scintigraphy in humans","volume":"95","author":"Ibekwe","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0075","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-5173(01)00897-3","article-title":"Simulated intestinal fluid as transport medium in the Caco-2 cell culture model","volume":"232","author":"Ingels","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2025.107095_bib0076","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/gut.10.4.267","article-title":"Small intestinal histochemical and histological changes in ulcerative colitis","volume":"10","author":"Jankey","year":"1969","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2025.107095_bib0077","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.3390\/cells12131730","article-title":"Novel small molecules in IBD: current State and future perspectives","volume":"12","author":"Jefremow","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ejps.2025.107095_bib0078","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejpb.2021.01.007","article-title":"Sustained-release hot melt extrudates of the weak acid TMP-001: a case study using PBB modelling","volume":"160","author":"Jung","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2025.107095_bib0079","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s11095-006-0207-8","article-title":"Canine intestinal contents vs. Simulated Media for the assessment of solubility of two weak bases in the Human small intestinal contents","volume":"23","author":"Kalantzi","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2025.107095_bib0080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bpg.2016.02.007","article-title":"Physiology of intestinal absorption and secretion","volume":"30","author":"Kiela","year":"2016","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.ejps.2025.107095_bib0081","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0011-393X(98)85095-9","article-title":"Expression of intestinal drug-metabolizing enzymes in patients with chronic inflammatory bowel disease","volume":"59","author":"Klotz","year":"1998","journal-title":"Curr. Ther. Res."},{"key":"10.1016\/j.ejps.2025.107095_bib0082","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MOG.0000000000000287","article-title":"Animal models of inflammatory bowel disease: how useful are they really?","volume":"32","author":"Kolios","year":"2016","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.ejps.2025.107095_bib0083","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/10837450.2012.696268","article-title":"Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer","volume":"17","author":"Krishnaiah","year":"2012","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejps.2025.107095_bib0084","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2023-100012","article-title":"Horizon scanning: new and future therapies in the management of inflammatory bowel disease","volume":"1","author":"Kumar","year":"2023","journal-title":"eGastroenterology"},{"key":"10.1016\/j.ejps.2025.107095_bib0085","first-page":"196","article-title":"Intestinal physiology relevant to short-bowel syndrome","volume":"9","author":"Kvietys","year":"1999","journal-title":"Eur J Pediatr Surg Off J Austrian Assoc Pediatr Surg Al Z Kinderchir"},{"key":"10.1016\/j.ejps.2025.107095_bib0086","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.xphs.2020.09.034","article-title":"Insight into the colonic disposition of Sulindac in humans","volume":"110","author":"Lemmens","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0087","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/ibd.21502","article-title":"Bile acid malabsorption in inflammatory bowel disease:assessment by serum markers","volume":"17","author":"Lenicek","year":"2011","journal-title":"Inflamm. Bowel. Dis."},{"key":"10.1016\/j.ejps.2025.107095_bib0088","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1023\/A:1012121632357","article-title":"Jejunal permeability: a comparison between the Ussing Chamber technique and the single-pass perfusion in humans","volume":"14","author":"Lennern\u00e4s","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2025.107095_bib0089","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/js970332a","article-title":"Human intestinal permeability","volume":"87","author":"Lennern\u00e4s","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0090","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejps.2013.08.025","article-title":"Regional intestinal drug permeation: biopharmaceutics and drug development","volume":"57","author":"Lennern\u00e4s","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0091","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejps.2013.08.025","article-title":"Regional intestinal drug permeation: biopharmaceutics and drug development","volume":"57","author":"Lennern\u00e4s","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0092","first-page":"275","article-title":"Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model","volume":"29","author":"Leonard","year":"2012","journal-title":"ALTEX - Altern Anim Exp"},{"key":"10.1016\/j.ejps.2025.107095_bib0093","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1021\/mp1000795","article-title":"A three-dimensional coculture of enterocytes, monocytes and dendritic cells to model inflamed intestinal mucosa in vitro","volume":"7","author":"Leonard","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2025.107095_bib0094","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.gastro.2011.04.011","article-title":"Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis","volume":"141","author":"Lepage","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2025.107095_bib0095","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1023\/A:1012107801889","article-title":"Characterization of fluids from the stomach and proximal jejunum in men and women","volume":"14","author":"Lindahl","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2025.107095_bib0096","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00423-021-02295-6","article-title":"State-of-the-art surgery for ulcerative colitis","volume":"406","author":"Liu","year":"2021","journal-title":"Langenbecks. Arch. Surg."},{"key":"10.1016\/j.ejps.2025.107095_bib0097","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-230X-9-19","article-title":"Validation study of villous atrophy and small intestinal inflammation in Swedish biopsy registers","volume":"9","author":"Ludvigsson","year":"2009","journal-title":"BMC. Gastroenterol."},{"key":"10.1016\/j.ejps.2025.107095_bib0098","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-2036.2001.00910.x","article-title":"Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease","volume":"15","author":"Lundin","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2025.107095_bib0099","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/gut.2005.073817","article-title":"Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach","volume":"55","author":"Manichanh","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2025.107095_bib0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijpharm.2008.05.012","article-title":"Gut instincts: explorations in intestinal physiology and drug delivery","volume":"364","author":"McConnell","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2025.107095_bib0101","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/10611860902839502","article-title":"Colonic treatments and targets: issues and opportunities","volume":"17","author":"McConnell","year":"2009","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejps.2025.107095_bib0102","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1053\/gast.2001.24845","article-title":"Colonic epithelial hPepT1 expression occurs in inflammatory bowel disease: transport of bacterial peptides influences expression of MHC class 1 molecules","volume":"120","author":"Merlin","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2025.107095_bib0103","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/628157","article-title":"Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut","volume":"2015","author":"Michielan","year":"2015","journal-title":"Mediators. Inflamm."},{"key":"10.1016\/j.ejps.2025.107095_bib0104","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1016062224568","article-title":"Estimation of the increase in solubility of drugs as a function of bile salt concentration","volume":"13","author":"Mithani","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2025.107095_bib0105","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1002\/jps.23609","article-title":"Establishment of novel prediction system of intestinal absorption in humans using Human intestinal tissues","volume":"102","author":"Miyake","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0106","first-page":"369","article-title":"Impairment of small intestinal function in ulcerative colitis: role of enteric innervation","volume":"11","author":"Mourad","year":"2017","journal-title":"J. Crohns. Colitis."},{"key":"10.1016\/j.ejps.2025.107095_bib0107","first-page":"1666","article-title":"Chemistry and biology of bile acids","volume":"87","author":"Mukhopadhyay","year":"2004","journal-title":"Curr. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0108","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1021\/acs.molpharmaceut.7b00095","article-title":"Magnetic resonance imaging quantification of fasted State colonic liquid pockets in healthy humans","volume":"14","author":"Murray","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2025.107095_bib0109","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.xphs.2019.12.015","article-title":"Comparison of the intestinal drug permeation and accumulation between normal Human intestinal tissues and Human intestinal tissues with ulcerative colitis","volume":"109","author":"Nakai","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0110","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/gut.23.9.751","article-title":"Bile acid absorption kinetics in Crohn's disease on elemental diet after oral administration of a stable-isotope tracer with chenodeoxycholic-11, 12-d2 acid","volume":"23","author":"Nishida","year":"1982","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2025.107095_bib0111","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.crohns.2014.03.003","article-title":"Sequential capsule endoscopy of the small bowel for follow-up of patients with known Crohn's disease","volume":"8","author":"Niv","year":"2014","journal-title":"J. Crohns. Colitis."},{"key":"10.1016\/j.ejps.2025.107095_bib0112","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2036.1990.tb00496.x","article-title":"Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers","volume":"4","author":"Norlander","year":"1990","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Supplement 1","key":"10.1016\/j.ejps.2025.107095_bib0113","doi-asserted-by":"crossref","first-page":"A45","DOI":"10.1016\/S1590-8658(00)80222-4","article-title":"Gut pH and transit time in ulcerative colitis appear sufficient for complete dissolution of pH-dependent 5-ASA-containing capsules","author":"Nugent","year":"2000","journal-title":"Dig. Liver. Dis."},{"key":"10.1016\/j.ejps.2025.107095_bib0114","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/jphp.12957","article-title":"Food for thought: formulating away the food effect \u2013 a PEARRL review","volume":"71","author":"O'Shea","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107095_bib0115","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.cgh.2013.07.001","article-title":"Intestinal permeability defects: is it time to treat?","volume":"11","author":"Odenwald","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejps.2025.107095_bib0116","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1095-6433(00)00330-5","article-title":"The control of gut motility","volume":"128","author":"Olsson","year":"2001","journal-title":"Comp. Biochem. Physiol. a Mol. Integr. Physiol."},{"key":"10.1016\/j.ejps.2025.107095_bib0117","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/0016-5085(86)90873-5","article-title":"Intraluminal pH in the stomach, duodenum, and proximal jejunum in normal subjects and patients with exocrine pancreatic insufficiency","volume":"90","author":"Ovesen","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2025.107095_bib0118","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1365-2036.2011.04938.x","article-title":"Noncoeliac enteropathy: the differential diagnosis of villous atrophy in contemporary clinical practice","volume":"35","author":"Pallav","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2025.107095_bib0119","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","article-title":"Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse","volume":"21","author":"Papamichael","year":"2015","journal-title":"Inflamm. Bowel. Dis."},{"key":"10.1016\/j.ejps.2025.107095_bib0120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF02209146","article-title":"Physiological regulation of transepithelial impedance in the intestinal mucosa of rats and hamsters","volume":"100","author":"Pappenheimer","year":"1987","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.ejps.2025.107095_bib0121","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.dld.2023.04.003","article-title":"The global, regional, and national burden of inflammatory bowel diseases, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"55","author":"Park","year":"2023","journal-title":"Dig. Liver. Dis."},{"key":"10.1016\/j.ejps.2025.107095_bib0122","series-title":"Concepts Models Drug Permeability Stud [Internet]","first-page":"57","article-title":"3.3 - Cell-based in vitro models for intestinal permeability studies","author":"Pereira","year":"2016"},{"key":"10.1016\/j.ejps.2025.107095_bib0123","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40262-015-0351-6","article-title":"Predicting drug extraction in the Human gut wall: assessing contributions from drug metabolizing enzymes and transporter proteins using preclinical models","volume":"55","author":"Peters","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2025.107095_bib0124","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.prp.2013.12.010","article-title":"Expression of selected cytochrome P450 isoforms and of cooperating enzymes in colorectal tissues in selected pathological conditions","volume":"210","author":"Plewka","year":"2014","journal-title":"Pathol. - Res. Pract."},{"key":"10.1016\/j.ejps.2025.107095_bib0125","doi-asserted-by":"crossref","first-page":"G275","DOI":"10.1152\/ajpgi.1981.241.4.G275","article-title":"Barrier function of epithelia","volume":"241","author":"Powell","year":"1981","journal-title":"Am. J. Physiol.-Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejps.2025.107095_bib0126","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/gut.27.Suppl_1.67","article-title":"Protein metabolism in inflammatory bowel disease","volume":"27","author":"Powell-Tuck","year":"1986","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2025.107095_bib0127","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1097\/MIB.0000000000000504","article-title":"Mechanisms underlying dysregulation of electrolyte absorption in IBD associated diarrhea","volume":"21","author":"Priyamvada","year":"2015","journal-title":"Inflamm. Bowel. Dis."},{"key":"10.1016\/j.ejps.2025.107095_bib0128","series-title":"Committee 2 IC on RPTG of. Report of the Task Group on Reference Man","year":"1975"},{"key":"10.1016\/j.ejps.2025.107095_bib0129","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00535-017-1324-3","article-title":"Systematic review with meta-analysis: loss of response and requirement of anti-tnf\u03b1 dose intensification in Crohn's disease","volume":"52","author":"Qiu","year":"2017","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.ejps.2025.107095_bib0130","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.gie.2018.08.006","article-title":"Quantitative assessment of mucosal architecture using computer-based analysis of confocal laser endomicroscopy in inflammatory bowel diseases","volume":"89","author":"Qu\u00e9n\u00e9herv\u00e9","year":"2019","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.ejps.2025.107095_bib0131","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1007\/s10620-013-2694-x","article-title":"Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease","volume":"58","author":"Rana","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0132","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/bjsm.2003.006825","article-title":"Objective evaluation of small bowel and colonic transit time using pH telemetry in athletes with gastrointestinal symptoms","volume":"38","author":"Rao","year":"2004","journal-title":"Br. J. Sports Med."},{"key":"10.1016\/j.ejps.2025.107095_bib0133","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/00365529009091905","article-title":"Gastrointestinal motility in patients with ulcerative colitis","volume":"25","author":"Rao","year":"1990","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.ejps.2025.107095_bib0134","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1007\/s11095-015-1710-6","article-title":"Characterization of contents of distal ileum and Cecum to which drugs\/drug products are exposed during bioavailability\/bioequivalence studies in healthy adults","volume":"32","author":"Reppas","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2025.107095_bib0135","unstructured":"Russell T.L., Dressman J.B., Barnett J.L., Dermentzoglou L.C., Jarvenpaa K.M., Schmaltz S.P., et al. Upper gastrointestinal (GI) pH in young, healthy men and women. 1990 [cited 2023 May 17]; Available from: http:\/\/deepblue.lib.umich.edu\/handle\/2027.42\/41548."},{"key":"10.1016\/j.ejps.2025.107095_bib0136","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/gut.20.12.1072","article-title":"Bile acid studies in patients with Crohn's colitis","volume":"20","author":"Rutgeerts","year":"1979","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2025.107095_bib0137","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.1.5438.827","article-title":"Small-intestinal and gastric abnormalities in ulcerative colitis","volume":"1","author":"Salem","year":"1965","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejps.2025.107095_bib0138","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1365-2125.2011.04019.x","article-title":"Drug\u2212disease interaction: crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity","volume":"72","author":"Sanaee","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107095_bib0139","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2036.2005.02683.x","article-title":"Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging","volume":"22","author":"Schiller","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2025.107095_bib0140","doi-asserted-by":"crossref","first-page":"G200","DOI":"10.1152\/ajpgi.1985.248.2.G200","article-title":"Intestinal membrane lipid composition and fluidity during development in the rat","volume":"248","author":"Schwarz","year":"1985","journal-title":"Am. J. Physiol.-Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejps.2025.107095_bib0141","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejps.2008.07.005","article-title":"Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole","volume":"35","author":"Seideg\u00e5rd","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-5173(93)90121-U","article-title":"The role of the gastrointestinal microflora in the metabolism of drugs","volume":"97","author":"Shamat","year":"1993","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2025.107095_bib0143","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1002\/cpz1.143","article-title":"Electrophysiologic analysis of tight junction size- and charge-selectivity","volume":"1","author":"Shashikanth","year":"2021","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.ejps.2025.107095_bib0144","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejps.2017.04.016","article-title":"pH-dependent solubility and permeability profiles: a useful tool for prediction of oral bioavailability","volume":"105","author":"Sieger","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0145","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3390\/12081859","article-title":"Exploitation of bile acid transport systems in prodrug design","volume":"12","author":"Siev\u00e4nen","year":"2007","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2025.107095_bib0146","first-page":"166","article-title":"Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique","volume":"48","author":"Sj\u00f6berg","year":"2013","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0147","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0016-5085(99)70551-2","article-title":"Epithelial permeability to proteins in the noninflamed ileum of Crohn's disease?","volume":"117","author":"S\u00f6derholm","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2025.107095_bib0148","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1021\/mp100144v","article-title":"Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids","volume":"7","author":"S\u00f6derlind","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2025.107095_bib0149","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/0016-5085(93)90974-H","article-title":"Showdown at the tight junction","volume":"105","author":"Soergel","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2025.107095_bib0150","unstructured":"Soler A.P., Miller R.D., Laughlin K.V., Carp N.Z., Klurfeld D.M., Mullin J.M. Increased tight junctional permeability is associated with the development of colon cancer."},{"key":"10.1016\/j.ejps.2025.107095_bib0151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2008.07.009","article-title":"The gastrointestinal microbiota as a site for the biotransformation of drugs","volume":"363","author":"Sousa","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2025.107095_bib0152","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1242\/jeb.204.10.1673","article-title":"Transport of bile acids in hepatic and non-hepatic tissues","volume":"204","author":"St-Pierre","year":"2001","journal-title":"J. Exp. Biol."},{"key":"10.1016\/j.ejps.2025.107095_bib0153","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000198583","article-title":"Serum prednisolone levels in Crohn's disease and coeliac disease following oral prednisolone administration","volume":"21","author":"Tanner","year":"2009","journal-title":"Digestion"},{"key":"10.1016\/j.ejps.2025.107095_bib0154","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1021\/mp800261a","article-title":"Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment","volume":"6","author":"Tannergren","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2025.107095_bib0155","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1111\/j.1462-2920.2009.01982.x","article-title":"Towards the human intestinal microbiota phylogenetic core","volume":"11","author":"Tap","year":"2009","journal-title":"Environ. Microbiol."},{"key":"10.1016\/j.ejps.2025.107095_bib0156","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1002\/jps.22726","article-title":"Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions","volume":"100","author":"Thelen","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0157","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/0884533613490740","article-title":"Consequences of gastrointestinal surgery on drug absorption","volume":"28","author":"Titus","year":"2013","journal-title":"Nutr. Clin. Pract."},{"key":"10.1016\/j.ejps.2025.107095_bib0158","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2025.107095_bib0159","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s11095-007-9519-6","article-title":"Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms","volume":"25","author":"Tubic-Grozdanis","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2025.107095_bib0160","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2025.107095_bib0161","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1021\/js970218s","article-title":"Membrane transport of drugs in different regions of the intestinal tract of the rat","volume":"87","author":"Ungell","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0162","article-title":"The role of intestinal permeability in gastrointestinal disorders and current methods of evaluation","volume":"8","author":"Vanuytsel","year":"2021","journal-title":"Front. Nutr. [Internet]"},{"key":"10.1016\/j.ejps.2025.107095_bib0163","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s11095-010-0158-y","article-title":"Characterization of the ascending colon fluids in ulcerative colitis","volume":"27","author":"Vertzoni","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2025.107095_bib0164","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/cts.12938","article-title":"Effect of Crohn's Disease on villous length and CYP3A4 expression in the pediatric small intestine","volume":"14","author":"Vyhlidal","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejps.2025.107095_bib0165","series-title":"Physiological Pharmaceutics: Barriers to Drug Absorption","author":"Washington","year":"2000"},{"key":"10.1016\/j.ejps.2025.107095_bib0166","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.gtc.2012.06.006","article-title":"Diarrhea in chronic inflammatory bowel diseases","volume":"41","author":"Wenzl","year":"2012","journal-title":"Gastroenterol. Clin. North Am."},{"key":"10.1016\/j.ejps.2025.107095_bib0167","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/MIB.0000000000001062","article-title":"CYP3A4 Activity is markedly lower in patients with Crohn's Disease","volume":"23","author":"Wilson","year":"2017","journal-title":"Inflamm. Bowel. Dis."},{"key":"10.1016\/j.ejps.2025.107095_bib0168","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.addr.2007.07.003","article-title":"Mouse models of inflammatory bowel disease","volume":"59","author":"Wirtz","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2025.107095_bib0169","doi-asserted-by":"crossref","first-page":"190","DOI":"10.15585\/mmwr.mm6706a4","article-title":"Health-risk behaviors and chronic conditions among adults with inflammatory bowel disease \u2014 United States, 2015 and 2016","volume":"67","author":"Xu","year":"2018","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.ejps.2025.107095_bib0170","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/17425247.2018.1389889","article-title":"Low colonic absorption drugs: risks and opportunities in the development of oral extended release products","volume":"15","author":"Xu","year":"2018","journal-title":"Expert. Opin. Drug Deliv."},{"key":"10.1016\/j.ejps.2025.107095_bib0171","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/ibd.21621","article-title":"Gene expression of carnitine organic cation transporters 1 and 2 (OCTN) is downregulated in patients with ulcerative colitis","volume":"17","author":"Yamamoto-Furusho","year":"2011","journal-title":"Inflamm. Bowel. Dis."},{"key":"10.1016\/j.ejps.2025.107095_bib0172","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jcph.787","article-title":"Utility of model-based approaches for informing dosing recommendations in specific populations: report from the public AAPS Workshop","volume":"57","author":"Younis","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107095_bib0173","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-019-1291-3","article-title":"Mapping human microbiome drug metabolism by gut bacteria and their genes","volume":"570","author":"Zimmermann","year":"2019","journal-title":"Nature"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725000946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725000946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:08:36Z","timestamp":1760227716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725000946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":173,"alternative-id":["S0928098725000946"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107095","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecule drug absorption in inflammatory bowel disease and current implementation in physiologically- based pharmacokinetic models","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107095"}}